Compass TherapeuticsCMPX -1.07%23 Earnings Yield (Joel Greenblatt) % is -9.79% as of Mar. 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,336 Biotechnology companies, Compass Therapeutics ranks worse than 73.5% on this metric.
Compass Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $767.77 Mil.
Compass Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-75.17 Mil. Compass Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -9.79%.
The historical rank and industry rank for Compass Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CMPX'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1594.8 Med: -23.48 Max: 674.9
Current: -32.36
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Compass Therapeutics was 674.90%. The lowest was -1594.80%. And the median was -23.48%.
CMPX's Earnings Yield (Joel Greenblatt) % is ranked worse than 73.5% of 1336
companies
in the Biotechnology industry
Industry Median: -9.745
vs CMPX: -32.36
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Compass Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Compass Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Compass Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Compass Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Compass Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Compass Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Compass Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.17 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -9.79% mean?
Compass Therapeutics (CMPX) has a Earnings Yield (Joel Greenblatt) % of -9.79% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Compass Therapeutics and its competitors. According to the industry distribution chart, Compass Therapeutics ranks #982 out of 1336 companies in the Biotechnology industry, placing it in the top 73.5%.
Is Compass Therapeutics' Earnings Yield (Joel Greenblatt) % too high?
Compass Therapeutics' current Earnings Yield (Joel Greenblatt) % is -9.79%. Based on the distribution chart, Compass Therapeutics ranks #982 out of 1336 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Earnings Yield (Joel Greenblatt) % compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #982 out of 1336 companies for Earnings Yield (Joel Greenblatt) %. This places Compass Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Compass Therapeutics and its competitors. Compass Therapeutics's current Earnings Yield (Joel Greenblatt) % is -9.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Earnings Yield (Joel Greenblatt) % of -9.79%. The current Earnings Yield (Joel Greenblatt) % is -9.79%. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Earnings Yield (Joel Greenblatt) % is -9.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score
Get the complete analysis for CMPX
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
